Novel immunotherapeutic options for BCG-unresponsive high-risk non-muscle-invasive bladder cancer.

ABSTRACT:

Background

High-risk non-muscle-invasive bladder cancer (HR-NMIBC) presents a challenge to many physicians due to its ability to resist Bacillus Calmette-Guérin (BCG) intravesical therapy and the substantial rate of progression into muscle-invasive bladder cancer (MIBC). Patients who are BCG-unresponsive have worse prognosis and thus require further management including radical cystectomy (RC), which significantly impacts quality of life. Moreover, the ongoing worldwide shortage of BCG warrants the need for policies that prioritize drug use and utilize alternative treatment strategies. Hence, there is a significant unmet need for bladder preserving therapy in this subset of patients.

Methods

To address this issue, we searched the relevant literature in PUBMED for articles pu

SUBMITTER: Hannouneh ZA 

PROVIDER: S-EPMC10757155 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature